Skip to main content Accessibility help

Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study

  • M. Harrow (a1), T. H. Jobe (a1) and R. N. Faull (a1)



The prevailing standard of care in the field involves background assumptions about the importance of prolonged use of antipsychotic medications for all schizophrenia (SZ) patients. However, do all SZ patients need antipsychotics indefinitely? Are there factors that help to identify which SZ patients can enter into prolonged periods of recovery without antipsychotics? This 20-year longitudinal research studied these issues.


A total of 139 early young psychotic patients from the Chicago Follow-up Study, including 70 patients with SZ syndromes and 69 with mood disorders, were assessed, prospectively, at the acute phase and then followed up six times over the next 20 years. Patients were assessed with standardized instruments for major symptoms, psychosocial functioning, personality, attitudinal variables, neurocognition and treatment.


At each follow-up, 30–40% of SZ patients were no longer on antipsychotics. Starting at the 4.5-year follow-ups and continuing thereafter, SZ patients not on antipsychotics for prolonged periods were significantly less likely to be psychotic and experienced more periods of recovery; they also had more favorable risk and protective factors. SZ patients off antipsychotics for prolonged periods did not relapse more frequently.


The data indicate that not all SZ patients need treatment with antipsychotics continuously throughout their lives. SZ patients not on antipsychotics for prolonged periods are a self-selected group with better internal resources associated with greater resiliency. They have better prognostic factors, better pre-morbid developmental achievements, less vulnerability to anxiety, better neurocognitive skills, less vulnerability to psychosis and experience more periods of recovery.


Corresponding author

*Address for correspondence: M. Harrow, Ph.D., University of Illinois at Chicago, Department of Psychiatry, 1601 W. Taylor (M/C 912), PI, Rm. 445, Chicago, IL 60612, USA. (Email:


Hide All
American DiabetesAssociation (2004). Consensus development conference on antipsychotic drugs and obesity. Diabetes Care 27, 596601.
Bland, R, Parker, J, Orn, H (1978). Prognosis in schizophrenia: prognostic predictors and outcome. Archives of General Psychiatry 35, 7277.
Bleuler, M (1978). The Schizophrenic Disorders: Long-Term Patient and Family Studies. Yale University Press: New Haven.
Bola, J, Mosher, L (2002). At issue: predicting drug-free treatment response in acute psychosis from the Soteria project. Schizophrenia Bulletin 28, 559575.
Bonner-Jackson, A, Harrow, M, Rosen, C (2010). Neurocognition in schizophrenia: a 20-year multi-follow-up of the course of processing speed and stored knowledge. Comprehensive Psychiatry 51, 471479.
Bosveld-van Haandel, L, Slooff, C, van den Bosch, R (2001). Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments. Acta Psychiatrica Scandinavica 103, 335346.
Buchanan, R, Kreyenbuhl, J, Kelly, D, Noel, J, Boggs, D, Fischer, B, Himelhoch, S, Fang, B, Peterson, E, Aquino, P, Keller, W (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 36, 7193.
Burdick, K, Harrow, M, Goldberg, J (2006). Neurocognition as a stable endophenotype in bipolar disorder and schizophrenia. Journal of Nervous and Mental Disease 194, 255267.
Carone, J, Harrow, M, Westermeyer, J (1991). Posthospital course and outcome in schizophrenia. Archives of General Psychiatry 48, 247253.
Carpenter, Jr. WT, Appelbaum, PS, Levine, RJ (2003). The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia. American Journal of Psychiatry 160, 356362.
Chouinard, G, Jones, BD (1980). Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. American Journal of Psychiatry 137, 1621.
Cohen, P, Cohen, J (1984). The clinician's illusions. Archives of General Psychiatry 41, 11781182.
Cornblatt, BA, Carrión, RE, Addington, J, Seidman, L, Walker, EF, Cannon, TD, Cadenhead, KS, McGlashan, TH, Perkins, DO, Tsuang, MT (2011). Risk factors for psychosis: impaired social and role functioning. Schizophrenia Bulletin. Published online: 10 November 2011. doi:10.1093/schbul/sbr136.
Dibben, C, Rice, C, Laws, K, McKenna, P (2009). Is executive impairment associated with schizophrenic syndromes? A meta-analysis. Psychological Medicine 39, 381392.
Endicott, J, Spitzer, R (1978). A diagnostic interview. Archives of General Psychiatry 35, 837844.
Fenton, W, McGlashan, T (1987). Sustained remission in drug-free schizophrenic patients. American Journal of Psychiatry 144, 13061309.
Gilbert, PL, Harris, MJ, McAdams, LA, Jeste, DV (1995). Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Archives of General Psychiatry 52, 173188.
Goldberg, J, Harrow, M (eds) (1999). Bipolar Disorders: Clinical Course and Outcome. American Psychiatric Press: Washington, DC.
Gorham, D (1956). A proverbs test for clinical and experimental use. Psychological Reports 2, 112.
Gottesman, I, Shields, J (1982). Schizophrenia: The Epigenetic Puzzle. Cambridge University Press: New York.
Grinker, R, Harrow, M (eds) (1987). Clinical Research in Schizophrenia: A Multidimensional Approach. Charles C. Thomas: Springfield, IL.
Gur, RE, Calkins, ME, Gur, RC, Horan, WP, Nuechterlein, KH, Seidman, LJ, Stone, WS (2007). The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes. Schizophrenia Bulletin 33, 4968.
Harding, C, Brooks, G, Ashikiga, T, Strauss, J, Breier, A (1987). The Vermont longitudinal study of persons with severe mental illness: II. Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. American Journal of Psychiatry 144, 727735.
Harrison, G, Hopper, K, Craig, T, Laska, E, Siegel, C, Wanderling, J, Dube, K, Ganev, K, Giel, R, an der Heiden, W, Holmberg, SK, Janca, A, Lee, PW, Leon, CA, Malhotra, S, Marsella, AJ, Nakane, Y, Sartorius, N, Shen, Y, Skoda, C, Thara, R, Tsirkin, SJ, Varma, VK, Walsh, D, Wiersma, D (2001). Recovery from psychotic illness: a 15- and 25-year international follow-up study. British Journal of Psychiatry 178, 506517.
Harrow, M, Goldberg, J, Grossman, L, Meltzer, H (1990). Outcome in manic disorders: a naturalistic follow-up study. Archives of General Psychiatry 47, 665671.
Harrow, M, Grossman, L, Herbener, E, Davis, E (2000). Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders, and mood-incongruent psychotic symptoms. British Journal of Psychiatry 177, 421426.
Harrow, M, Grossman, L, Jobe, T, Herbener, E (2005). Do patients with schizophrenia ever show periods of recovery? A 15-year multi-follow-up study. Schizophrenia Bulletin 31, 723734.
Harrow, M, Hansford, B, Astrachan-Fletcher, E (2009). Locus of control: relation to schizophrenia, to recovery, and to depression and psychosis – a 15-year longitudinal study. Psychiatry Research 168, 186192.
Harrow, M, Jobe, T (2007). Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multi-follow-up study. Journal of Nervous and Mental Disease 195, 406414.
Harrow, M, Jobe, T (2010). How frequent is chronic multiyear delusional activity and recovery in schizophrenia: a 20-year multi-follow-up. Schizophrenia Bulletin 36, 192204.
Harrow, M, Jobe, T, Astrachan-Fletcher, E (2008). Prognosis of persecutory delusions in schizophrenia: a 20-year longitudinal study. In Persecutory Delusions: Assessment, Theory and Treatment (ed. Freeman, D., Garety, P. and Bentall, R.), pp. 7390. Oxford University Press: Oxford.
Ho, BC, Andreasen, NC, Ziebell, S, Pierson, R, Magnotta, V (2011). Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Archives of General Psychiatry 68, 128137.
Jobe, T, Harrow, M (2005). Long-term outcome of patients with schizophrenia: a review. Canadian Journal of Psychiatry 50, 892900.
Jobe, T, Harrow, M (2010). Schizophrenia course, long-term outcome, recovery, and prognosis. Current Directions in Psychological Science 19, 220225.
Jones, P, Murray, R, Rodgers, B, Marmot, M (1994). Child developmental risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 344, 13981402.
Katz, M, Lyerly, S (1963). Methods for measuring adjustment and social behavior in the community: I. Rationale, description, discriminative, validity and scale development. Psychological Reports 13, 503535.
Kendler, K, Neale, M (2010). Endophenotype: a conceptual analysis. Molecular Psychiatry 15, 789797.
Kreyenbuhl, J, Buchanan, R, Dickerson, F, Dixon, L (2010). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophrenia Bulletin 36, 94–103.
Lehtinen, V, Aaltonen, J, Koffert, T, Räkköläinen, V, Syvälahti, E (2000). Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed? European Psychiatry 15, 312320.
Levenstein, D, Klein, D, Pollack, M (1966). Follow-up study of formerly hospitalized voluntary psychiatric patients: the first two years. American Journal of Psychiatry 122, 11021109.
Lieberman, J, Stroup, S, McEvoy, J, Swartz, M, Rosenheck, R, Perkins, D, Keefe, R, Davis, S, Davis, C, Lebowitz, B, Severe, J, Hsiao, J (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 12091223.
Marengo, J, Harrow, M, Rogers, C (1980). A Manual for Scoring Abstract and Concrete Responses to the Proverbs Test. ASIS/NAPS No. 03646. Microfiche Publications: New York.
Menezes, N, Arenovich, T, Zipursky, R (2006). A systematic review of longitudinal outcome studies of first-episode psychosis. Psychological Medicine 36, 13491362.
Moncrieff, J (2009). A critique of the dopamine hypothesis of schizophrenia and psychosis. Harvard Review of Psychiatry 17, 214225.
Moncrieff, J, Leo, J (2010). A systematic review of the effects of antipsychotic drugs on brain volume. Psychological Medicine 40, 14091422.
Owens, DC, Johnstone, EC, Miller, P, Macmillan, JF, Crow, TJ (2010). Duration of untreated illness and outcome in schizophrenia: test of predictions in relation to relapse risk. British Journal of Psychiatry 196, 296301.
President's New Freedom Commission on Health (2003). Achieving the Promise: Transforming Mental Health Care in America. University of Michigan Library: Ann Arbor, MI.
Reed, R, Harrow, M, Herbener, E, Martin, E (2002). Executive function in schizophrenia: is it linked to psychosis and poor life functioning? Journal of Nervous and Mental Disease 190, 725732.
Remington, G, Kapur, S (2010). Antipsychotic dosing: how much but also how often? Schizophrenia Bulletin 36, 900903.
Samaha, AN, Seeman, P, Stewart, J, Rajabi, H, Kapur, S (2007). ‘Breakthrough’ dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. Journal of Neuroscience 27, 29792986.
Stephens, J, Pascal, R, McHugh, P (1997). Long-term follow-up of patients hospitalized for schizophrenia, 1913 to 1940. Journal of Nervous and Mental Disorders 185, 715721.
Strauss, J, Carpenter, W (1972). The prediction of outcome in schizophrenia: I. Characteristics of outcome. Archives of General Psychiatry 27, 739746.
Tandon, R, Belmaker, R, Gattaz, WF (2008). World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophrenia Research 100, 2038.
Vaillant, G (1978). A 10-year follow-up of remitting schizophrenics. Schizophrenia Bulletin 4, 7885.
Ventura, J, Subotnik, KL, Guzik, LH, Hellemann, GS, Gitlin, MJ, Wood, RC, Nuechterlein, KH (2011). Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophrenia Research 132, 1823.
Webber, MA, Marder, SR (2008). Better pharmacotherapy for schizophrenia: what does the future hold? Current Psychiatry Reports 10, 352358.
Wechsler, D (1955). Weschler Adult Intelligence Scale Manual. Psychological Corporation: New York.
White, C, Stirling, J, Hopkins, R, Morris, J, Montague, L, Tantam, D, Lewis, S (2009). Predictors of 10-year outcome of first-episode psychosis. Psychological Medicine 39, 14471456.
Zigler, E, Glick, M (2001). The developmental approach to adult psychopathology. Clinical Psychologist 54, 2–11.
Zigler, E, Levine, J (1983). Hallucinations vs. delusions: a developmental approach. Journal of Nervous and Mental Disease 171, 141146.


Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study

  • M. Harrow (a1), T. H. Jobe (a1) and R. N. Faull (a1)


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed